Cargando…

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials

Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical trials, the efficacy and safety of nivol...

Descripción completa

Detalles Bibliográficos
Autores principales: Knetki-Wróblewska, Magdalena, Kowalski, Dariusz M., Krzakowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408765/
https://www.ncbi.nlm.nih.gov/pubmed/32708936
http://dx.doi.org/10.3390/jcm9072273
_version_ 1783567907639263232
author Knetki-Wróblewska, Magdalena
Kowalski, Dariusz M.
Krzakowski, Maciej
author_facet Knetki-Wróblewska, Magdalena
Kowalski, Dariusz M.
Krzakowski, Maciej
author_sort Knetki-Wróblewska, Magdalena
collection PubMed
description Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical trials, the efficacy and safety of nivolumab in real-world practice were not certain. In general, the real-world results of nivolumab treatment have been consistent with those obtained in clinical trials. Additional analyses of the real-world data have made the identification of prognostic factors possible. Good performance status is the most significant predictor of clinical benefit. Brain metastases, liver metastases, EGFR mutation, malignant pleural effusion, and a high number of metastatic sites were identified as negative prognostic factors. By contrast, a longer time to disease progression (>6 months) from the beginning of prior chemotherapy and an objective response to chemotherapy seem to have positive prognostic value in the case of nivolumab treatment. In terms of patient age, the data are inconclusive. Some blood biomarkers can also be considered significant prognostic factors.
format Online
Article
Text
id pubmed-7408765
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74087652020-08-13 Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials Knetki-Wróblewska, Magdalena Kowalski, Dariusz M. Krzakowski, Maciej J Clin Med Review Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical trials, the efficacy and safety of nivolumab in real-world practice were not certain. In general, the real-world results of nivolumab treatment have been consistent with those obtained in clinical trials. Additional analyses of the real-world data have made the identification of prognostic factors possible. Good performance status is the most significant predictor of clinical benefit. Brain metastases, liver metastases, EGFR mutation, malignant pleural effusion, and a high number of metastatic sites were identified as negative prognostic factors. By contrast, a longer time to disease progression (>6 months) from the beginning of prior chemotherapy and an objective response to chemotherapy seem to have positive prognostic value in the case of nivolumab treatment. In terms of patient age, the data are inconclusive. Some blood biomarkers can also be considered significant prognostic factors. MDPI 2020-07-17 /pmc/articles/PMC7408765/ /pubmed/32708936 http://dx.doi.org/10.3390/jcm9072273 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Knetki-Wróblewska, Magdalena
Kowalski, Dariusz M.
Krzakowski, Maciej
Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
title Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
title_full Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
title_fullStr Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
title_full_unstemmed Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
title_short Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
title_sort nivolumab for previously treated patients with non-small-cell lung cancer—daily practice versus clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408765/
https://www.ncbi.nlm.nih.gov/pubmed/32708936
http://dx.doi.org/10.3390/jcm9072273
work_keys_str_mv AT knetkiwroblewskamagdalena nivolumabforpreviouslytreatedpatientswithnonsmallcelllungcancerdailypracticeversusclinicaltrials
AT kowalskidariuszm nivolumabforpreviouslytreatedpatientswithnonsmallcelllungcancerdailypracticeversusclinicaltrials
AT krzakowskimaciej nivolumabforpreviouslytreatedpatientswithnonsmallcelllungcancerdailypracticeversusclinicaltrials